文献速递白血病

医疗保险受益的慢性髓性白血病患者中酪氨酸激酶抑制剂启动与依从性的相关因素

Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2016-10-31

该研究利用SEER-Medicare数据,纳入2007至2011年诊断的393例慢性髓性白血病(CML)医疗保险受益人,分析酪氨酸激酶抑制剂(TKI)的启动与依从性。68%在诊断后180天内启动TKI,有费用分担补贴、较年轻、合并症较少及诊断年份较晚者更可能启动TKI;启动者中61%依从。无费用分担补贴者启动延迟,提示自付费用可能是及时启动治疗的障碍。

要点

  • 393例CML医疗保险受益人中,68%在诊断后180天内启动TKI治疗。
  • 有费用分担补贴、较年轻、合并症较少及诊断年份较晚者更可能启动TKI。
  • TKI启动者中61%依从;80岁及以上者依从性低于66至69岁者。

核心结论

  • 仅68%的CML医疗保险受益人在诊断后6个月内启动TKI治疗。
  • 无费用分担补贴者启动延迟,提示自付费用可能是及时启动治疗的障碍。

研究设计与样本

  • 利用SEER-Medicare数据,识别2007至2011年诊断的CML个体。
  • 采用Cox比例风险回归评估从诊断到TKI启动的时间。
  • 采用广义估计方程分析180天内治疗启动及启动者的TKI依从性。
  • 依从性定义为TKI启动后6个月内覆盖天数至少80%。

主要发现

  • 393例CML患者中,68%在诊断后180天内启动TKI治疗。
  • 多变量分析中,有费用分担补贴、较年轻、合并症较少及诊断年份较晚者显著更可能启动TKI。
  • TKI启动者中61%依从。
  • 80岁及以上者依从性低于66至69岁者。

关键数值与推荐

  • 依从性定义为TKI启动后6个月内覆盖天数至少80%。
  • 启动时间评估为诊断后180天内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose There is substantial concern surrounding affordability of orally administered anticancer therapies, particularly for Medicare beneficiaries. We examined rates of initiation and adherence to tyrosine kinase inhibitors (TKIs) among Medicare beneficiaries with chronic myeloid leukemia (CML) with and without cost-sharing subsidies. We selected TKIs given their effectiveness and strong indication for use among patients diagnosed with CML. Patients and Methods Using SEER-Medicare data, we identified individuals diagnosed with CML from 2007 to 2011. We used Cox proportional hazards regression to assess time from diagnosis to TKI initiation. We used generalized estimating equations to examine treatment initiation within 180 days and TKI adherence among initiators. We defined adherence as at least 80% of days covered during the 6 months after TKI initiation. Results Among 393 individuals diagnosed with CML from 2007 to 2011, 68% initiated TKI treatment within 180 days after diagnosis. In multivariate analysis, individuals with cost-sharing subsidies, younger age, lower comorbidity, and later year of diagnosis were significantly more likely to initiate TKIs. Among TKI initiators, 61% were adherent; adherence was lower for individuals age 80 years or older versus 66 to 69 years. Conclusion Only 68% of Medicare beneficiaries with CML initiated TKI therapy within 6 months of diagnosis. Delayed initiation among individuals without cost-sharing subsidies suggests that out-of-pocket costs may be a barrier to timely initiation of therapy among individuals diagnosed with CML.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Winn AN, Keating NL, Dusetzina SB, et al. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. J Clin Oncol. 2016. PMID: 27998234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。